Peter Aspesi

TL;DR: The results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents and the generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of ‘personalized’ therapeutic regimens.

TL;DR: Jordi Barretina, Giordano Caponigro, Nicolas Stransky, Kavitha Venkatesan, Adam A. Golub, Michael P. Morais, Jodi Meltzer, Judit Jané-Valbuena, Felipa A. Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H. Engels, Jill Cheng, Guoying K. Yu

TL;DR: Biochemical and genetic evidence support an overlapping binding site of 1 with the anti-cancer compound didemnin B on EF-1α, and this myxobacterial chemotype offers an interesting starting point for further investigations of the potential of therapeutics targeting elongation factor 1.

TL;DR: The dampening of InsP3-mediated signaling affects Ca2+ release, modulates defense gene expression and compromises plant defense responses, shows that phosphoinositide signaling is one component of the plant defense network and is involved in both basal and systemic responses.

TL;DR: This work has assembled a chemogenetic library by data mining and crowdsourcing institutional expertise, and is sharing the approach, lessons learned, and disclosing the current collection of 4,185 compounds with their primary annotated gene targets.